CytoSorbents to Present at the Long Island Capital Alliance Health Care Capital Forum on March 8, 2013

CytoSorbents to Present at the Long Island Capital Alliance Health Care Capital 
Forum on March 8, 2013 
MONMOUTH JUNCTION, NJ -- (Marketwire) -- 03/05/13 --  CytoSorbents
Corporation (OTCBB: CTSO), a critical care focused company using
blood purification to treat life-threatening illnesses, today
announced that Dr. Phillip Chan, Chief Executive Officer, will
present at the Long Island Capital Alliance (LICA) Health Care
Capital Forum on March 8, 2013. The capital forum will be held in
collaboration with The Center for Advanced Sensor Technologies at
Stony Brook University.  
Conference Details:
 Date and Time: 
 March 8, 2013, 8:00 a.m. -
10:30 a.m. 
Location:
 The RXR Corporate Center
 68 South Service
Rd., Melville, New York 
The presenting companies to be showcased at LICA's Health Care
Capital Forum were selected by LICA for this event from a wide
selection of developing medical technology, life sciences and health
care information technology companies on Long Island and the nearby
region. Several of the presenting companies provide best-in-class
solutions to enhance medical related diagnostics and therapies as
well as health care administration and productivity advancements.
Each of the companies selected for presentation will provide a
discussion of their technology, product of service, a financial
overview and catalysts for significant growth.  
For more information or to register for the event please contact your
LICA representative or register online by visiting
http://www.licapital.org/licapital/.  
About the Long Island Capital Alliance:
 Since 1984, the Long Island
Capital Alliance (www.licapital.org), formerly known as Long Island
Venture Group, has been promoting business growth on Long Island.
LICA seeks to create a productive and business-friendly environment
that will afford area businesses access to the resources necessary to
compete successfully in today's markets. LICA serves as a focal point
for the exchange of ideas among new and existing business
enterprises, successful entrepreneurs, investors, and service
providers. Through quarterly capital forums and special meetings,
LICA brings together members of the region's business community, and
has been recognized as the place to turn to when small businesses
need equity, debt,
 or other financing, or for investors to find an
attractive investment opportunity. 
LICA's mission is to encourage economic development on Long Island by
facilitating capital formation for a broad range of companies in
various industries, from early stage to mature middle market closely
held and publicly-traded businesses. LICA accomplishes this primarily
through education, networking, quarterly capital forums, periodic
special educational meetings, and alliances with other regional
organizations. LICA brings together members of the region's business
community and serves as the finance arm for significant local
business and organizations.  
For more information on LICA and its next event, please contact LICA
today or register online. 
About CytoSorbents Corporation
 CytoSorbents Corporation is a
critical care focused therapeutic device company using blood
purification to treat life-threatening illnesses commonly seen in the
intensive care unit such as sepsis and infection, influenza, severe
lung injury, trauma, burn injury, and pancreatitis. Its purification
technology is based upon biocompatible, highly porous polymer beads
that can efficiently remove toxic substances from blood and other
bodily fluids. The Company's flagship product CytoSorb(R), a
first-in-class extracorporeal cytokine filter compatible with
standard hemodialysis machines, has achieved European Union CE Mark
regulatory approval and is now being commercialized in Europe. The
goal of the CytoSorb(R) cytokine filter is to prevent or treat
multiple organ failure, the leading cause of death in the intensive
care unit, by reducing the excessive production of cytokines, or
"cytokine storm," that could otherwise lead to deadly inflammation,
organ injury, and death. Organ failure represents one of the most
serious unmet medical needs in modern medicine, claiming millions of
lives around the world, at a cost of hundreds of billions of dollars,
each year. By actively addressing one of the most important
underlying causes of organ failure, CytoSorb(R) represents a
potentially revolutionary advance in the treatment of critical
illnesses.  
CytoSorbents has been awarded contracts from both DARPA and the US
Army, and continues to invest significantly in its research and
development pipeline. One of its most advanced products under
development is HemoDefend, a blood purification technology platform
for the blood transfusion industr
y intended to reduce transfusion
reactions and improve the safety of "old" blood by removing many
substances, such as antibodies, free hemoglobin and inflammatory
mediators that can cause potentially serious and sometimes fatal
transfusion reactions.  
CytoSorb(R) and HemoDefend are just two of a number of different
polymers the Company has developed for various medical applications,
including improved dialysis, reduction of post-surgical complications
in cardiac surgery, treatment of inflammatory and autoimmune
disorders, radio-imaging contrast removal in imaging and
interventional radiology procedures, and the treatment of
rhabdomyolysis, drug overdose, and others. Additional information is
available for download on the Company's website:
http://www.cytosorbents.com.  
Company Contact:
CytoSorbents Corporation
Dr. Phillip Chan 
Chief Executive Officer 
(732) 329-8885 ext. *823 
pchan@cytosorbents.com  
Investor Contact:
Alliance Advisors, LLC
Alan Sheinwald
(914) 669-0222
asheinwald@allianceadvisors.net 
Valter Pinto
(914) 669-0222 x201
valter@allianceadvisors.net 
 
 
Press spacebar to pause and continue. Press esc to stop.